Copenhagen, Denmark, September 8, 2023 – Brace yourself for a transformative event as Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a pioneering biotechnology company dedicated to pioneering peptide-based medicines, announces a groundbreaking Obesity R&D Event slated for December 5, 2023, in the vibrant city of London. This event promises to be a convergence of top-tier management and external scientific luminaries in the realm of obesity research.
The global surge in obesity and its related health challenges has placed an immense burden on healthcare systems worldwide. Zealand Pharma, armed with a formidable pipeline of innovative drug candidates, is at the forefront of reshaping the future of obesity management. Adam Steensberg, the visionary President and Chief Executive Officer of Zealand Pharma, affirmed, “The December 5th Obesity R&D day is set to be an illuminating experience, where we will delve deep into the scientific foundation and clinical promise of our product candidates, alongside esteemed experts in the field.”
Stay tuned for forthcoming announcements regarding event timing, venue, and registration logistics, ensuring that investors, analysts, and scientific aficionados can be part of this transformative occasion in person. Prepare to witness the future of obesity research unfold before your eyes.
About Zealand Pharma
Meet Zealand Pharma, a visionary biotechnology powerhouse on a relentless quest to revolutionize healthcare through the discovery and development of groundbreaking peptide-based medicines. With an awe-inspiring track record, Zealand has ushered over 10 innovative drug candidates into clinical development, a testament to their unwavering commitment to medical advancement. Among these pioneers, two have already graced the market, while three others stand at the precipice of late-stage development, poised to transform patient care.
Zealand’s dedication to progress extends beyond their labs, as they’ve forged strategic development partnerships with esteemed pharmaceutical companies and nurtured commercial partnerships for their market-ready products. Founded in 1998, Zealand calls Copenhagen, Denmark, its home, but its influence extends across the Atlantic, with a strong presence in the dynamic hub of Boston, USA. Zealand Pharma isn’t just redefining medicine; it’s rewriting the future of healthcare.